sutures newsletter

PRODUCED BY AND FOR MEMBERS OF THE DEPARTMENT OF SURGERY August 2014 | Archived Issues

P and T Approvals, Tramadol Change, Warnings About Promacta and Sporanox

Pharmacy Focus

See highlights of the June 3 meeting of the Pharmacy and Therapeutics Committee. Also, tramadol is now being managed as a controlled substance, and the federal government has released a warning about Promacta and a list of contraindications for Sporanox.


Mark Your Calendar


Surgery Grand Rounds

Click the "read more" to see information about upcoming Surgery Grand Rounds.


Grand Rounds

Click here to view a schedule of all upcoming grand rounds.


Education Schedule

Click the PDF link below to see the Department of Surgery's educational schedule.

Educational Schedule - August 2014 (PDF)


Surgery Scheduling

Click the "read more" for hours and contact information for surgery scheduling.

Share Your News

Know an interesting colleague we should profile? A story we should tell? Submit your ideas, meetings and events for consideration.

Click here to submit your news to Sutures

Vo Honored for Kidney Transplant Work

Ashley Anh Vo, PharmD

Ashley Anh Vo, PharmD, administrative director of the Transplant Immunotherapy Program at the Cedars-Sinai Comprehensive Transplant Center, has been named the 2014 Clinician of Distinction by the American Society of Transplantation for her work in developing anti-rejection drug protocols for patients.

"This prestigious award recognizes Dr.Vo’s clinical excellence and the creative scholarship she brings to the field of transplantation," said Andrew S. Klein MD, director of the Cedars-Sinai Comprehensive Transplant Center. "This is a unique achievement that represents her dedication and tireless work on behalf of transplant patients."

Vo, an associate professor in the Department of Medicine, received the award at the recent World Transplant Congress in San Francisco, an international gathering where Cedars-Sinai kidney transplant clinicians and researchers contributed nearly 30 abstracts and presentations. One of the most highly anticipated presentations involved preliminary research of a new anti-rejection drug known as C1-INH by Stanley C. Jordan, MD, director of Kidney Transplantation and Transplant Immunology at Cedars-Sinai. Patients in the small trial who received C1-INH after transplantation developed fewer complications than those who did not receive the drug.

Vo’s research in immunotherapy began in 1994, when she became the transplant pharmacist at Cedars-Sinai and joined a National Institutes of Health investigation headed by Jordan. Since then, Vo and Jordan have collaborated extensively, producing the 2004 landmark study that identified new anti-rejection treatments.

That study tested IVIG, intravenous immunoglobulin, as an effective therapy for lowering a patient’s level of HLA antibodies, which can cause a patient’s body to reject a transplanted organ. Patients who have been pregnant, been on kidney dialysis or received many blood transfusions often develop HLA antibodies, making it very hard for them to have a successful kidney transplant.

"Dr. Vo has played a key role in our research identifying how IVIG treatment significantly reduces the long amount of time a patient can remain on dialysis, suffering, waiting for a suitable transplant because their HLA antibody levels put them at a high risk of organ rejection," Jordan said. "Her work has been an important asset to the entire field of organ transplantation."